Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety/Tolerability Effects of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor (FXR) Agonist in Healthy Subjects and in Subjects with Presumptive Nonalcoholic Fatty Liver Disease